Cannabis stocks offer an excellent entry point after a procedural pause in the DEA rescheduling hearing triggered near-panic selling. The industry has never been closer to rescheduling and resolving custody and uplisting issues, and it recently refinanced its debt on excellent rate and duration terms. The pause until October 13 may delay rescheduling somewhat but is unlikely to derail it, and institutional investors should begin entering over the rest of the year. x.com 

Enforcement of hemp/THCA restrictions is critical to reshaping the cannabis industry and could be its next major lever. The view follows observations in wholesale hemp/THCA distribution, without specifying what those observations showed. x.com 

MSOS's underlying cannabis operators burn cash, dilute shareholders frequently and have poor management, so waiting for US regulatory reform still entails substantial time decay. x.com 

Trump's push to reclassify cannabis from Schedule I to Schedule III is a massive tailwind for the sector, including multi-state operators and Cronos Group. It would end the 280E tax that has crushed margins for years, letting companies deduct normal business expenses and instantly boosting cash flow, profitability and valuations. x.com  x.com 

British American Tobacco carries cannabis optionality that few big companies admit to, and Big Tobacco will lean into cannabis hard rather than pull back. BAT describes a "foothold in the cannabis space" that is "several years away from being a meaningful contributor". @UseThouBrain, in the post being answered, backs Organigram on the view that BAT's idea of meaningful means billions, backed by patent-pending non-combustible IP; that is a different bet, far down the field, but not a bad one. … Show more

IM Cannabis's 107% jump on a letter of intent to buy 51% of a drone company looks likely to fade, since the pivot to UAVs and defense is speculative. The company recently did a 30:1 reverse split and has a history of dilution, and with a $5.2M market cap and 550K float the move points back toward $5. x.com 

Aurora Cannabis merger-arbitrage is harder now because the initial bid-bump opportunity has passed. The shares still trade surprisingly tight in this market; if another bidder comes over the top, the event opportunity opens again. x.com  x.com 

WM Technology is not worth buying even after its fall, because there are many better options. Some holders likely owned it only because it was Nasdaq-listed and compliant, and the illiquidity premium is hard to price. @_OuttaControl argues it already traded under 1x sales with no value assigned to the business, and @Moneyman_2017 warns trading will get weird on the OTC market. Even on a standalone view of cannabis and software it would be tempting, but it is a pass. x.com  x.com 

Glass House Brands is falling apart, down 66% since June, and its business will stay tough until regulation changes. x.com 

IM Cannabis has short-squeeze potential: its float is a micro 603,200 shares, 12% of it is sold short and no shares are left to borrow, with fresh news and volume adding pressure. Remaining warrants, including those at $19 and $99, could lift the share count to about 780,000. x.com